The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 ...

Asahi Kasei, a global provider of healthcare and pharmaceutical solutions, announced that Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules), has been included ...

First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory ...

AVEO Oncology, an LG Chem company (AVEO), and HiberCell, Inc. (HiberCell) announced today that the companies have entered ...

Scientists at Wake Forest University School of Medicine have discovered a new way to kill cancer cells by blocking their ...

A new compound called CMX410 may change the fight against tuberculosis. It targets a weak point in the bacteria’s defenses, ...

Upadacitinib treatment was associated with reduced non-nociceptive pain among patients with axSpA, including both neuropathic and nociplastic types.

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its cardiovascular portfolio at the American Heart Association’s Scientific Sessions 2025, taking place November 7–10, ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported ...